GeoVax Targets Immunologically Cold Tumors with Gedeptin Combination Strategies
GeoVax disclosed that Gedeptin, when administered alongside existing immunotherapies, exhibits synergistic anti-tumor activity in models of immunologically cold tumors. The company is preparing clinical development plans for Gedeptin-based combination regimens targeting solid tumors with low immune infiltration.
1. Announcement of Gedeptin Role
GeoVax announced that its investigational vaccine candidate Gedeptin demonstrated enhanced anti-tumor efficacy when combined with checkpoint inhibitors in immunologically cold tumor models. The findings indicate improved immune cell recruitment and tumor growth inhibition beyond monotherapy outcomes.
2. Clinical Development Plans
Following these preclinical results, GeoVax is outlining a roadmap to launch phase I combination trials in patients with solid tumors characterized by low baseline immune infiltration. The company aims to collaborate with oncology centers to evaluate safety and preliminary efficacy in resistant tumor types.